Furthermore, there is preliminary interest inapplying these therapies to maturity-onset diabetes of the young (MODY) subtypes,particularly those with features of insulin resistance or hepatic steatosis [16].These findings underscore the evolving role of incretin-based therapies inaddressing the complex interplay of glucose metabolism, adiposity, andinflammation across diverse cardiometabolic phenotypes. The gene discussed is GCG; the disease is Hepatic steatosis.